《2014年临床肿瘤学新进展学术研讨会――》由会员分享，可在线阅读，更多相关《2014年临床肿瘤学新进展学术研讨会――（14页珍藏版）》请在金锄头文库上搜索。
1、2014年临床肿瘤学新进展学术研讨会Best of ASCO Event in China 2014会议日程Program会议第一天 2014年7月11日 (Day 1, July 11, 2014)8:008:15 开幕式 (Opening Ceremony)CSCO代表：吴一龙教授 致辞 (Opening speech by Prof. Yi-Long Wu on behalf of CSCO)ASCO代表：Peter Yu教授 致辞 (Opening speech by Prof. Peter Yu on behalf of ASCO)血液肿瘤专场 (Hematologic Malign
2、ancy) 主席(Chair)：马 军(Jun Ma)、王健民(Jian-Min Wang)时间(Time)题目(Topic)讲者(Speaker)8:158:40Abstract 7005Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). BiTE antibody
3、 blinatumomab在复发/难治性急性前体B淋巴细胞白血病患者（r/ r ALL）的验证性多中心、开放标签的单臂2期研究。糜坚青(Jian-Qing Mi)Abstract 7008Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. ibrutinib与ofatumumab在
4、复发或难治性（R/R）慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的随机比较：来自RESONATE 期试验的结果。Abstract 7026Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial.Ruxolitinib（RUX）在羟基脲耐药或不能耐受的真性红细胞增多症（PV）患者的前瞻性、随
5、机、开放标签的期研究结果：RESPONSE试验。8:408:50专家评述Discussion Topic: A comprehensive overview on molecular targeted therapy for leukemia讨论主题：白血病分子靶向治疗综述李建勇(Jian-Yong Li)8:508:55讨论(Q & A)马 军(Jun Ma)王健民(Jian-Min Wang)李建勇(Jian-Yong Li)泌尿系统肿瘤专场1 (Genitourinary Cancer Session 1) 主席(Chair)：叶定伟(Ding-Wei Ye)、马建辉(Jian-Hui
6、Ma)时间(Time)题目(Topic)讲者(Speaker)8:559:20Abstract LBA2Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. 一项ECOG领导的 III期随机临床试验：激素敏感的新发转移性前列腺癌患者（mPrCa）接受化疗联合内分泌治疗对比单用内分
7、泌治疗对于总生存期(OS)的影响。戴 波(Bo Dai)Abstract 5003Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. PSA复发的前列腺癌患者接受立即雄激素剥夺治疗与延迟雄激素剥夺治疗的比较。Abstract 5008 Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in
8、patients (pts) with chemotherapy-nave metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). 三期、随机、安慰剂对照临床试验（ELM-PC 4试验）：orteronel(tak - 700)联合强的松治疗未接受过化疗的转移性去势抵抗型前列腺癌患者（mCRPC）的研究。9:209:30专家评述Discussion Topic: Feasibility of combined therapy for patients with hormone-sensitive pro
9、state cancer讨论主题：对激素敏感型前列腺癌患者进行联合治疗的可行性何志嵩(Zhi-Song He)9:309:35讨论(Q & A)叶定伟(Ding-Wei Ye)马建辉(Jian-Hui Ma)何志嵩(Zhi-Song He)泌尿系统肿瘤专场2 (Genitourinary Cancer Session 2)主席(Chair)：周芳坚(Fang-Jian Zhou)、谢晓冬(Xiao-Dong Xie)时间(Time)题目(Topic)讲者(Speaker)9:3510:00Abstract 5009Nivolumab for metastatic renal cell carc
10、inoma (mRCC): Results of a randomized, dose-ranging phase II trial. Nivolumab治疗转移性肾细胞癌（mRCC):一项随机的关于剂量调整的II期临床研究结果。姚 欣(Xin Yao)Abstract 5011Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).MPDL3280A抑制PD-L1及其对转移性膀胱尿路上皮癌患者的临床作用。Abstract 5012
11、Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.Nivolumab对经治和未治转移性肾细胞癌的免疫调节活性：基于生物标志物的随机临床试验结果。10:0010:10专家评述Discussion Topic: Immunotherapy for RCC?讨论主题：肾癌细胞免疫治疗？王秀问(Xiu-Wen W
12、ang)10:1010:15讨论(Q & A)周芳坚(Fang-Jian Zhou)谢晓冬(Xiao-Dong Xie)王秀问(Xiu-Wen Wang)10:15-10:30 休息 Break恶性黑色素瘤专场 (Melanoma Session)主席(Chair)：郭 军(Jun Guo)、梁 军(Jun Liang)时间(Time)题目(Topic)讲者(Speaker)10:3010:55Abstract 9000Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) w
13、ith melanoma (MEL).抗PD-1单抗（MK-3475）治疗411例黑色素瘤患者的疗效和安全性研究结果。斯 璐(Lu Si)Abstract LBA9008Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. Ipillimumab与安慰剂辅助治疗III期黑色素瘤术后患者的III期对照研究（EORTC18071）：初步疗效和安全性结果。Abs
14、tract 9003Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma.抗PD-1单抗nivolumab（BMS-）联合Ipilimumab（IPI）治疗不同BRAF基因突变状态的晚期黑色素瘤患者的生存、疗效持续时间和活化情况的影响。10:55-11:05专家评述Discussion Topi
15、c: Adjuvant immunotherapy for resectable melanoma?讨论主题：可手术黑色素瘤的辅助免疫治疗？张晓实(Xiao-Shi Zhang)11:05-11:10讨论(Q & A)郭 军(Jun Guo)梁 军(Jun Liang)张晓实(Xiao-Shi Zhang)胃肠肿瘤专场1 (Gastrointestinal Cancer Session 1)主席(Chair)：沈 琳(Lin Shen)、徐建明(Jian-Ming Xu)时间(Time)题目(Topic)讲者(Speaker)11:10-11:35Abstract 4003Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo- controlled trial. 阿帕替尼治疗晚期胃癌的随机、双盲、安慰剂对照的III期临床研究。张小田(Xiao-Tian Zhang)Abstract 4005RAINBOW: A global, phase III, randomi
